Dr. No

Three 'Busted' Biotech IPOs: Amicus, Jazz, Sirtris

"it is hard to imagine all three will stay below or at their IPO price for too long."

Well, for the not so familiar with biotech, here is the bad news: Most companies that went public recently (i.e. in the last three years) traded at or below IPO.

But maybe some of the Jazz drugs just make imagining the reality hard...